Last reviewed · How we verify

busulfex — Competitive Intelligence Brief

busulfex (busulfex) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Matrix metalloproteinase-9 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

busulfex (busulfex) — Dana-Farber Cancer Institute.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
busulfex TARGET busulfex Dana-Farber Cancer Institute marketed Matrix metalloproteinase-9
CEFOTIAM CEFOTIAM marketed cefotiam Vasoactive intestinal polypeptide receptor 1, Matrix metalloproteinase-9, Bacterial penicillin-binding protein 1988-01-01
Monocid CEFONICID marketed cefonicid Matrix metalloproteinase-9 1984-01-01
Dtic-Dome dacarbazine Bayer marketed Alkylating Drug [EPC] Matrix metalloproteinase-9 1975-01-01
Cefradex cefradine Bristol-Myers Squibb marketed cefradine Matrix metalloproteinase-9 1974-01-01
Busulfex busulfan Waylis marketed Alkylating Drug [EPC] Matrix metalloproteinase-9 1954-01-01
Beclometasone Beclometasone Imperial College London marketed Matrix metalloproteinase-9, Probable G-protein coupled receptor 97, Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). busulfex — Competitive Intelligence Brief. https://druglandscape.com/ci/busulfex. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: